Jonathan Rohrer

Group Leader

Jon leads the FTD talk team. He is a Principal Investigator at the Dementia Research Centre in the Queen Square UCL Institute of Neurology as well as a Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. After a Natural Sciences degree at the University of Cambridge he went on to do Medicine at the University of Oxford and UCL. He started as a Wellcome Trust Clinical Research Fellow in 2005 at UCL where he first began to study FTD, working on the neuroimaging of genetic FTD, and completing his PhD in 2010. He then became an NIHR Clinical Lecturer during which time he started the Genetic FTD Initiative, GENFI, an international multicentre cohort study of presymptomatic genetic FTD. This was followed by an NIHR Rare Diseases Translational Research Collaboration Clinical Research Fellowship in 2014 and then an MRC Clinician Scientist fellowship in 2015. The research of his team focuses on the development of novel biomarkers in frontotemporal dementia (FTD). He co-leads the UCL/UCLH Biomedical Research Centre Dementia Biomarkers Theme and sits on the UCL Neurogenetics Therapies Programme Clinical Steering Committee. Nationally, he also runs FTD UK, an annual scientific meeting of UK researchers who work in the FTD field, and the FTD and fFTD support groups through Rare Dementia Support. Internationally, as well as running GENFI, he co-leads the FTD Prevention Initiative (FPI), is vice-chair for the Alzheimer’s Association Professional Interest Area in FTD, and is co-chair for the ENIGMA-FTD group.

  • Danish Dementia Research Centre Annual Meeting (Copenhagen, November 2021): Update on GENFI and FPI
  • Wellcome Genome Campus Molecular Neurodegeneration Course (Cambridge [virtual], January 2021): Clinical aspects of neurodegenerative disease
  • Novel Gene Therapies in Neurology Conference (Leuven [virtual], September 2020): Clinical trial design in genetic FTD – opportunities and challenges
  • 2nd International C9orf72 workshop (London, January 2020): Clinical and imaging aspects of C9orf72 expansions
  • ABN Cognitive Special Interest Group Meeting 2020 (London, January 2020): Psychiatric complications of FTD
  • Wellcome Genome Campus Molecular Neurodegeneration Course (Cambridge, December 2019): Clinical aspects of neurodegenerative disease
  • West of England Seminars in Advanced Neurology (Exeter, November 2019): FTD – diagnostic and therapeutic prospects
  • ALLFTD 2019 (San Diego, November 2019): An update on GENFI
  • NISALS 2019 (Oxford, October 2019): 10 years of FTD imaging and the decade ahead
  • 1st UCL Queen Square Annual Motor Neuron Disease Symposium (London, September 2019): FTD and its overlap with ALS
  • Oxford MRI course 2019 (Oxford, July 2019): GENFI
  • Wolfson symposium (London, June 2019): GENFI
  • Bristol Neurology Grand Round (Bristol, June 2019): FTD – insights into a complex disorder
  • Birmingham Neurology Grand Round (Birmingham, April 2019): An update on FTD
  • Biomarkers Across Neurodegenerative Diseases (London, April 2019): Biomarkers in FTD
  • ADRD Summit 2019 (Bethesda, March 2019): Biomarkers in FTD
  • Swedish FTD Initiative (Stockholm, March 2019): GENFI – the story so far
  • AFTD Biomarkers Initiative 2019 (Miami, February 2019): Discovering novel fluid biomarkers for tau and TDP-43
  • Erasmus FTD Seminar (Rotterdam, November 2018): Neuroimaging of FTD
  • UK Neurogenetics Predictive Testing Consortium (Birmingham, July 2018): Clinical genetics of FTD
  • RCP Teach-In: Dementia (London, May 2018): 9 things to know about FTD
  • Neurology 2018: leading edge neurology for the practising clinician (London, April 2018): FTD
  • Young Onset Dementia Conference 2017 (London, November 2017): Recent advances in FTD
  • Imperial Neurology Grand Round (London, November 2017): An update on FTD
  • Wessex Neurology Grand Round (Southampton, September 2017): An update on FTD
  • King’s College Neurology Grand Round (London, September 2017): An update on FTD
  • EAN 2017 (Amsterdam, June 2017): Secondary prevention trials in dementia
  • ADPD 2017 (Vienna, April 2017): Developing biomarkers for FTD
  • FTD Alliance (Boston, February 2017): GENFI
  • International ALS/MND Symposium 2016 (Dublin, December 2016): Detecting early changes in FTD
  • Lancet Neurology Presymptomatic Medicine conference (London, October 2016): Biomarkers and early diagnosis of FTD
  • Oxford Neurology Course 2016 (Oxford, June 2016): GENFI
  • FTD Treatment Study Group 2016 (Washington, March 2016): GENFI
  • LEFFTDS/ARTFL 2016 (Washington, March 2016): GENFI
  • ARUK Conference 2016 (Manchester, March 2016): GENFI